Bagsværd, Denmark, 18 March 2016 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted:

Financial year 2015 and 2016

  • The Company's audited Annual Report 2015.
  • The actual remuneration of the Board of Directors for 2015 and the remuneration level for 2016.
  • Distribution of profit according to the adopted Annual Report 2015. The dividend will be DKK 6.40 per A and B share of DKK 0.20.

Elections

  • Re-election of Göran Ando as chairman and Jeppe Christiansen as vice chairman of the Board of Directors.
  • Re-election of Bruno Angelici, Sylvie Grégoire, Liz Hewitt and Mary Szela as members of the Board of Directors.
  • Election of Brian Daniels as new member of the Board of Directors.
  • Re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the Company's auditor.

Shares and capital
  • Reduction of the Company's B share capital by cancellation of part of the Company's own holding of B shares. The Company's B shares are reduced by DKK 10,000,000 from DKK 412,512,800 to DKK 402,512,800.
  • Authorisation to the Board of Directors to increase the Company's share capital.
  • Authorisation to the Board of Directors until the next Annual General Meeting to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital. 

Other

  • Amendments to the Articles of Association regarding
    • abolishment of bearer shares
    • the change of NASDAQ OMX Copenhagen A/S' name to Nasdaq Copenhagen A/S
    • deletion of the requirement that all members of the Executive Management shall be registered with the Danish Business Authority
    • company announcements may be prepared in English only, if decided by the Board of Directors 
       
  • Revised Remuneration Principles.

Composition of the Board of Directors and its committees

After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors, including its committees are now composed as follows:

  • Göran Ando (chairman of the Board, of the Nomination Committee and of the Remuneration Committee)
  • Jeppe Christiansen (vice chairman and member of the Remuneration Committee and the Audit Committee)
  • Bruno Angelici (member of the Nomination Committee)
  • Brian Daniels
  • Sylvie Grégoire (member of the Audit Committee)
  • Liz Hewitt (chairman of the Audit Committee and member of the Nomination Committee)
  • Liselotte Hyveled (employee representative and member of the Nomination Committee)
  •  Anne Marie Kverneland (employee representative)
  • Søren Thuesen Pedersen (employee representative and member of the Remuneration Committee)
  • Stig Strøbæk (employee representative and member of the Audit Committee)
  • Mary Szela (member of the Remuneration Committee)

Further information

Media:    
Katrine Sperling +45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 267 809 7552 kiau@novonordisk.com
 

Investors:
   
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje +45 3079 8519 kpvj@novonordisk.com
     

Company announcement No 23 / 2016


Company announcement No 23 / 2016



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1995860